Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.

Transplantation proceedings - 1 Apr 2018

Vondrák K, Seeman T

Abstract excerpt

Atypical hemolytic-uremic syndrome (aHUS) is an extremely rare disease, and up to 70% of the patients have a genetic mutation in the encoding components of complement activation or anti-complement factor H autoantibodies. The risk of recurrence after kidney transplantation is 10% to 80%. Eculizumab, a monoclonal antibody that binds complement protein C5, has shown to be highly effective in patients with aHUS;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atypical Hemolytic Uremic Syndrome

Share to Complement Activation

Share to Complement Factor H

Share to Kidney Transplantation

Share to Postoperative Complications

Share to Recurrence

Source

Identifiers

PMID: 29661469
DOI: 10.1016/j.transproceed.2018.02.012

Genes

CFH
CFHR1
CFHR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.PMID 29661469Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.Semantic proximity Read ↗

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.Semantic proximity Read ↗

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.Semantic proximity Read ↗

Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Liver transplantation for aHUS: still needed in the eculizumab era?Semantic proximity Read ↗

De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report.Semantic proximity Read ↗

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutation .Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.